Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Incorporating newer agents in the treatment of acute myeloid leukemia. Leuk Res 2018 Nov;74:113-120

Date

11/08/2018

Pubmed ID

30401522

DOI

10.1016/j.leukres.2018.10.008

Scopus ID

2-s2.0-85055577100   7 Citations

Abstract

Prognosis for patients with AML remains dismal. Despite multiple clinical trials across several decades, little improvement for the therapy of non-APL AML was noted. However, over the last couple of years, several new therapies have demonstrated efficacy in the therapy of patients with AML. Several of those have been approved by the FDA for AML therapy. These include CPX-351, midostaurin, gemtuzumab ozogamicin, enasidenib and ivosidenib. Our goal in this review is to summarize currently available data on these new therapies and discuss the rapidly evolving treatment landscape of AML.

Author List

Raj RV, Abedin SM, Atallah E

Authors

Sameem Abedin MD Assistant Professor in the Medicine department at Medical College of Wisconsin
Ehab L. Atallah MD Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Antineoplastic Agents
Drug Approval
Female
Humans
Leukemia, Myeloid, Acute
Male
United States
United States Food and Drug Administration